Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Heptares Therapeutics
LONDON and BOSTON, May 15, 2014 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, will give a company presentation at the UBS Global Healthcare Conference in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May.
In addition, senior scientists from Heptares will give scientific presentations at the following industry meetings over the coming weeks:
The 34th National Medicinal Chemistry Symposium (Charleston, SC, USA, 18-21 May)
Dr John Christopher, Heptares' Associate Director Chemistry, will present "Case Studies in GPCR Drug Design" at 1:30pm EDT on Wednesday 21 May.
14th Annual Structure-Based Drug Design (Boston, MA, USA, 21-22 May)
Dr Jon Mason, Heptares' Head of Computational Chemistry will present "High End GPCR Design: Crafted Ligand Design and Druggability Analysis Using Protein Structure, Lipophilic Hotspots and Explicit Water Networks" at 2:05pm EDT on Wednesday 21 May.
GTC GPCR Structure, Function and Drug Discovery (Boston, MA, USA, 22-23 May)
Dr Jon Mason will present "Structure Based Drug Discovery Applied to GPCRs" at 1:15pm EDT on
Thursday 22 May.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR is a registered trademark in the EU and Japan.
©2012 PR Newswire. All Rights Reserved.